Who is sponsoring NCT04754152?

NCT04754152 is sponsored by Anhui Medical University.

What drugs are being tested in NCT04754152?

Interventions in NCT04754152: θ burst transcranial magnetic stimulation, Pharmacotherapy.

What condition does NCT04754152 study?

NCT04754152 studies Repetitive Transcranial Magnetic Stimulation.

Is NCT04754152 still recruiting?

NCT04754152 is currently completed. Last updated 28 February 2023.

Last reviewed 2023-02-28 · How we verify

NCT04754152

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Long-term Effect of θ Burst Magnetic Stimulation on Clinical Symptoms of Alzheimer Disease

Completed NA Last updated 28 February 2023

What this trial tests

NA trial testing θ burst transcranial magnetic stimulation in Repetitive Transcranial Magnetic Stimulation in 45 participants. Completed in 31 December 2022.

Timeline

21 April 2021

Primary endpoint
17 May 2022

31 December 2022

Quick facts

Lead sponsor	Anhui Medical University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	45
Start date	21 April 2021
Primary completion	17 May 2022
Estimated completion	31 December 2022
Sites	1 location across China

Drugs / interventions tested

θ burst transcranial magnetic stimulation
Pharmacotherapy — full drug profile →

Conditions studied

Repetitive Transcranial Magnetic Stimulation — all drugs for Repetitive Transcranial Magnetic Stimulation →

Sponsor

Anhui Medical University

Who can join

Adults 50 to 80, any sex, with Repetitive Transcranial Magnetic Stimulation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This was a randomized, single-blind, parallel, placebo-controlled clinical trial assessing the efficacy of neuronavigational TBS among patients with AD. Fourty late-onset AD were included in the study, all the patients were divided into TBS groups and drug treatment group. Drug intervention group AD patients with drug regimen (donepezil 5mg / d) and primary care guidance, once every three months follow-up. TBS group is treated with TBS (a course of treatment every 3 months); after completing 4 treatments/follow-ups a year, evaluate the changes in MoCA, other clinical symptoms and multi-domain cognition tests, and brain Changes in structure and function.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Effects of a periodic intermittent theta burst stimulation in Alzheimer's disease.
Wu X, Yan Y, Hu P, Wang L, et al · · 2024 · cited 16× · PMID 38274292 · DOI 10.1136/gpsych-2023-101106
Repetitive Transcranial Magnetic Stimulation in the Treatment of Alzheimer's Disease and Other Dementias.
Aloizou AM, Pateraki G, Anargyros K, Siokas V, et al · · 2021 · cited 8× · PMID 34442086 · DOI 10.3390/healthcare9080949
The Potential for Neuromodulation in the Treatment of Alzheimer's Disease: A Review of Clinical Trials.
Jones T, Shalom M, Chalamgari A, Gold J, et al · · 2025 · PMID 40599507 · DOI 10.7759/cureus.85156

Verify or expand the search:

Other recruiting trials for Repetitive Transcranial Magnetic Stimulation

Currently open trials in the same condition.

NCT07173920 — Single-Center, Double-Blind, Randomized, Placebo-Controlled Study on Efficacy and Safety of rTMS (With Precise Localizat · NA · recruiting
NCT06757491 — Lf-rTMS Attenuates Visceral Pain in Irritable Bowel Syndrome With Diarrhea · NA · recruiting
NCT06762535 — fMRI Study of the Neural Mechanism of rTMS in the Treatment of Nicotine Dependence · NA · active not recruiting

Other Anhui Medical University trials

Trials by the same sponsor.

NCT07403591 — Mapsd Dual-target cTBS (Auditory Cortex and M1) for Generalized Anxiety Disorder · NA · not yet recruiting
NCT07112612 — Minimal Residual Disease Used in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Cancer · not yet recruiting
NCT07112599 — Study of Predicting Lymph Node Metastasis of High-risk Prostate Cancer by Artificial Intelligence Multi-omics Analysis · recruiting
NCT07176468 — Personalized iTBS in Real-World Clinical Settings for Schizophrenia · NA · recruiting
NCT07486804 — Effects of taVNS Combined With tACS on Adolescents With Non-Suicidal Self-Injury · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04754152 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Anhui Medical University
Last refreshed: 28 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04754152.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing